Premunition

Last updated
Graph depicting premunition in malaria. Adapted from
.mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}
White, Nicholas J; Pukrittayakamee, Sasithon; Hien, Tran Tinh; Faiz, M Abul; Mokuolu, Olugbenga A; Dondorp, Arjen M (2014). "Malaria". The Lancet. Elsevier BV. 383 (9918): 723-735. doi:10.1016/s0140-6736(13)60024-0. ISSN 0140-6736. PMID 23953767. S2CID 208794141. Premunition.jpg
Graph depicting premunition in malaria. Adapted from White, Nicholas J; Pukrittayakamee, Sasithon; Hien, Tran Tinh; Faiz, M Abul; Mokuolu, Olugbenga A; Dondorp, Arjen M (2014). "Malaria". The Lancet. Elsevier BV. 383 (9918): 723–735. doi:10.1016/s0140-6736(13)60024-0. ISSN   0140-6736. PMID   23953767. S2CID   208794141.

Premunition, also known as infection-immunity, is a host response that protects against high numbers of parasite and illness without eliminating the infection. [1] This type of immunity is relatively rapid, progressively acquired, short-lived, and partially effective. [2] For malaria, premunition is maintained by repeated antigen exposure from infective bites. [2] Thus, if an individual departs from an endemic area, he or she may lose premunition and become susceptible to malaria. [2]

Contents

Antibody action contributes to premunition. [3] However, premunition is probably much more complex than simple antibody and antigen interaction. [2] In the case of malaria, the sporozoite and merozoite stages of Plasmodium elicit the antibody response which leads to premunition. [3] Immunoglobulin E targets the parasites and leads to eosinophil degranulation which releases major basic protein that damages the parasites, and other factors elicit a local inflammatory response. [3] However, Plasmodium can change its surface antigens, so the development of an antibody repertoire that can recognize multiple surface antigens is important for premunition to be achieved. [4]

Premunition has not been well-studied, and although it likely occurs broadly, it is mainly emphasized for its role in malaria, tuberculosis, syphilis and relapsing fever. [5]

Premunization is the artificial induction of premunition. [6]

Premunity is progressive development of immunity in individuals exposed to an infective agent, [7] mainly belonging to protozoa and Rickettsia, but not in viruses. [8] After the initial infection, which generally occurs in childhood, the effect in subsequent infections is diminished. Infections thereafter may exhibit little or no symptomatology in spite of parasitemia. The next stage is resistance to infection altogether.

Loss of premunity is estimated to be the cause of the rebound of malaria [9] in 1965, in India after the dramatic success of the National Malaria Control Programme that was launched for rural India in 1953.

Premunity occurs in infections of babesiosis, [10] [11] malaria [7] [12] Onchocerca volvulus , [13] and Trichomonas . [14]

See also

Related Research Articles

<span class="mw-page-title-main">Antigen</span> Molecule triggering an immune response (antibody production) in the host

In immunology, an antigen (Ag) is any molecule, molecular structure, foreign particulate matter, or pollen grain that can bind to a specific antibody or T-cell receptor. The presence of antigens in the body may trigger an immune response. Antigens can be proteins, peptides, polysaccharides, lipids, or nucleic acids.

<span class="mw-page-title-main">Malaria</span> Medical condition

Malaria is a mosquito-borne infectious disease that affects humans and other animals. Malaria causes symptoms that typically include fever, tiredness, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death. Symptoms usually begin ten to fifteen days after being bitten by an infected mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria.

<span class="mw-page-title-main">Onchocerciasis</span> Human helminthiasis (infection by parasite)

Onchocerciasis, also known as river blindness, is a disease caused by infection with the parasitic worm Onchocerca volvulus. Symptoms include severe itching, bumps under the skin, and blindness. It is the second-most common cause of blindness due to infection, after trachoma.

<i>Plasmodium</i> Genus of parasitic protists that can cause malaria

Plasmodium is a genus of unicellular eukaryotes that are obligate parasites of vertebrates and insects. The life cycles of Plasmodium species involve development in a blood-feeding insect host which then injects parasites into a vertebrate host during a blood meal. Parasites grow within a vertebrate body tissue before entering the bloodstream to infect red blood cells. The ensuing destruction of host red blood cells can result in malaria. During this infection, some parasites are picked up by a blood-feeding insect, continuing the life cycle.

<i>Plasmodium falciparum</i> Protozoan species of malaria parasite

Plasmodium falciparum is a unicellular protozoan parasite of humans, and the deadliest species of Plasmodium that causes malaria in humans. The parasite is transmitted through the bite of a female Anopheles mosquito and causes the disease's most dangerous form, falciparum malaria. It is responsible for around 50% of all malaria cases. P. falciparum is therefore regarded as the deadliest parasite in humans. It is also associated with the development of blood cancer and is classified as a Group 2A (probable) carcinogen.

<span class="mw-page-title-main">Helminthiasis</span> Any macroparasitic disease caused by helminths

Helminthiasis, also known as worm infection, is any macroparasitic disease of humans and other animals in which a part of the body is infected with parasitic worms, known as helminths. There are numerous species of these parasites, which are broadly classified into tapeworms, flukes, and roundworms. They often live in the gastrointestinal tract of their hosts, but they may also burrow into other organs, where they induce physiological damage.

<i>Onchocerca volvulus</i> Nematode

Onchocerca volvulus is a filarial (arthropod-borne) nematode (roundworm) that causes onchocerciasis, and is the second-leading cause of blindness due to infection worldwide after trachoma. It is one of the 20 neglected tropical diseases listed by the World Health Organization, with elimination from certain countries expected by 2020.

<i>Plasmodium vivax</i> Species of single-celled organism

Plasmodium vivax is a protozoal parasite and a human pathogen. This parasite is the most frequent and widely distributed cause of recurring malaria. Although it is less virulent than Plasmodium falciparum, the deadliest of the five human malaria parasites, P. vivax malaria infections can lead to severe disease and death, often due to splenomegaly. P. vivax is carried by the female Anopheles mosquito; the males do not bite.

<i>Plasmodium malariae</i> Species of single-celled organism

Plasmodium malariae is a parasitic protozoan that causes malaria in humans. It is one of several species of Plasmodium parasites that infect other organisms as pathogens, also including Plasmodium falciparum and Plasmodium vivax, responsible for most malarial infection. Found worldwide, it causes a so-called "benign malaria", not nearly as dangerous as that produced by P. falciparum or P. vivax. The signs include fevers that recur at approximately three-day intervals – a quartan fever or quartan malaria – longer than the two-day (tertian) intervals of the other malarial parasites.

<i>Plasmodium knowlesi</i> Species of single-celled organism

Plasmodium knowlesi is a parasite that causes malaria in humans and other primates. It is found throughout Southeast Asia, and is the most common cause of human malaria in Malaysia. Like other Plasmodium species, P. knowlesi has a life cycle that requires infection of both a mosquito and a warm-blooded host. While the natural warm-blooded hosts of P. knowlesi are likely various Old World monkeys, humans can be infected by P. knowlesi if they are fed upon by infected mosquitoes. P. knowlesi is a eukaryote in the phylum Apicomplexa, genus Plasmodium, and subgenus Plasmodium. It is most closely related to the human parasite Plasmodium vivax as well as other Plasmodium species that infect non-human primates.

Antigenic variation or antigenic alteration refers to the mechanism by which an infectious agent such as a protozoan, bacterium or virus alters the proteins or carbohydrates on its surface and thus avoids a host immune response, making it one of the mechanisms of antigenic escape. It is related to phase variation. Antigenic variation not only enables the pathogen to avoid the immune response in its current host, but also allows re-infection of previously infected hosts. Immunity to re-infection is based on recognition of the antigens carried by the pathogen, which are "remembered" by the acquired immune response. If the pathogen's dominant antigen can be altered, the pathogen can then evade the host's acquired immune system. Antigenic variation can occur by altering a variety of surface molecules including proteins and carbohydrates. Antigenic variation can result from gene conversion, site-specific DNA inversions, hypermutation, or recombination of sequence cassettes. The result is that even a clonal population of pathogens expresses a heterogeneous phenotype. Many of the proteins known to show antigenic or phase variation are related to virulence.

Plasmodium yoelii is a parasite of the genus Plasmodium subgenus Vinckeia. As in all Plasmodium species, P. yoelii has both vertebrate and insect hosts. The vertebrate hosts for this parasite are mammals.

<span class="mw-page-title-main">Malaria antigen detection tests</span>

Malaria antigen detection tests are a group of commercially available rapid diagnostic tests of the rapid antigen test type that allow quick diagnosis of malaria by people who are not otherwise skilled in traditional laboratory techniques for diagnosing malaria or in situations where such equipment is not available. There are currently over 20 such tests commercially available. The first malaria antigen suitable as target for such a test was a soluble glycolytic enzyme Glutamate dehydrogenase. None of the rapid tests are currently as sensitive as a thick blood film, nor as cheap. A major drawback in the use of all current dipstick methods is that the result is essentially qualitative. In many endemic areas of tropical Africa, however, the quantitative assessment of parasitaemia is important, as a large percentage of the population will test positive in any qualitative assay.

<span class="mw-page-title-main">Malaria vaccine</span> Vaccine that is used to prevent malaria

A malaria vaccine is a vaccine that is used to prevent malaria. The only approved malaria vaccine is RTS,S, known by the brand name Mosquirix. As of April 2022, the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1-2 years. The vaccine reduces hospital admissions from severe malaria by around 30%.

<span class="mw-page-title-main">Mosquito-borne disease</span> Diseases caused by bacteria, viruses or parasites transmitted by mosquitoes

Mosquito-borne diseases or mosquito-borne illnesses are diseases caused by bacteria, viruses or parasites transmitted by mosquitoes. Nearly 700 million people get a mosquito-borne illness each year resulting in over 725,000 deaths.

Pregnancy-associated malaria (PAM) or placental malaria is a presentation of the common illness that is particularly life-threatening to both mother and developing fetus. PAM is caused primarily by infection with Plasmodium falciparum, the most dangerous of the four species of malaria-causing parasites that infect humans. During pregnancy, a woman faces a much higher risk of contracting malaria and of associated complications. Prevention and treatment of malaria are essential components of prenatal care in areas where the parasite is endemic – tropical and subtropical geographic areas. Placental malaria has also been demonstrated to occur in animal models, including in rodent and non-human primate models.

The mainstay of malaria diagnosis has been the microscopic examination of blood, utilizing blood films. Although blood is the sample most frequently used to make a diagnosis, both saliva and urine have been investigated as alternative, less invasive specimens. More recently, modern techniques utilizing antigen tests or polymerase chain reaction have been discovered, though these are not widely implemented in malaria endemic regions. Areas that cannot afford laboratory diagnostic tests often use only a history of subjective fever as the indication to treat for malaria.

<span class="mw-page-title-main">RTS,S</span> Malaria vaccine

RTS,S/AS01 is a recombinant protein-based malaria vaccine. It is the only malaria vaccine approved and in wide use. As of April 2022, the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1-2 years. The vaccine reduces hospital admissions from severe malaria by around 30%.

<i>Plasmodium cynomolgi</i> Species of single-celled organism

Plasmodium cynomolgi is an apicomplexan parasite that infects mosquitoes and Asian Old World monkeys. In recent years, a number of natural infections of humans have also been documented. This species has been used as a model for human Plasmodium vivax because Plasmodium cynomolgi shares the same life cycle and some important biological features with P. vivax.

<span class="mw-page-title-main">Lucy Graves Taliaferro</span> American parasitologist

Lucy Engel Graves Taliaferro was an American parasitologist and professor, notable for her research in parasitology and immunology. She and her husband, William Hay Taliaferro, worked together as research partners from 1919 to 1973. She worked as a researcher in her husband's parasitology laboratory for over 30 years at the University of Chicago, where she co-taught a parasitology course with William and achieved the rank of Assistant Professor, although she was never paid. After retiring from the University of Chicago in 1960, the Talioferros researched the effects of ionizing radiation on the immune response at Argonne National Laboratory and coauthored Radiation and Immune Mechanisms (1964).

References

  1. Ryan, Kenneth J.; Ray, C. George, eds. (2010). Sherris Medical Microbiology (5 ed.). ISBN   978-0-07-160402-4.
  2. 1 2 3 4 Jean Mouchet; Pierre Carnevale; Sylvie Manguin (2008). Biodiversity of Malaria in the World. John Libbey Eurotext. p. 41. ISBN   978-2-7420-0616-8 . Retrieved 23 June 2012.
  3. 1 2 3 Nandini Shetty; Julian W. Tang; Julie Andrews (19 May 2009). Infectious Disease: Pathogenesis, Prevention and Case Studies. John Wiley & Sons. p. 84. ISBN   978-1-4051-3543-6 . Retrieved 23 June 2012.
  4. Mandell, Gerald L.; Bennett, John E. (John Eugene); Dolin, Raphael. (2010). Mandell, Douglas, and Bennett's principles and practice of infectious disease. Philadelphia, PA: Churchill Livingstone/Elsevier. p. 3444. ISBN   978-0-443-06839-3.
  5. Kothari, M. L.; Lopa a, M. (1976). "The nature of immunity". Journal of Postgraduate Medicine. 22 (2): 50–58. PMID   1032677.
  6. H. (CON) Aspock (3 January 2008). Encyclopedia of Parasitology. Springer. p. 150. ISBN   978-3-540-48994-8 . Retrieved 23 June 2012.
  7. 1 2 "Effects of impregnated bednets". Modelling group at the Department of Medical Biometry, University of Tübingen. Retrieved 18 January 2014.
  8. Seifert, Horst S. H. (1 January 1996). Tropical Animal Health. Springer. p. 150. ISBN   978-0-7923-3821-5.
  9. "Reports of Expert Committees to the Interim Commission" (PDF). Official Records of the World Health Organisation No.8. April 1948.
  10. Shaw, Susan E.; Day, Michael J. (11 April 2005). Arthropod-borne Infectious Diseases of the Dog and Cat. Manson Publishing. p. 71. ISBN   978-1-84076-578-6.
  11. Hoyte, HMD (November 1961). "Initial Development of Infections with Babesia bigeminal*". The Journal of Protozoology. 8 (4): 462–466. doi:10.1111/j.1550-7408.1961.tb01242.x.
  12. Maegraith, B. G. (1 January 1973). "Malaria". Tropical Pathology. Spezielle pathologische Anatomie. Vol. 8. Springer Berlin Heidelberg. pp. 319–349. doi:10.1007/978-3-662-00226-1_11. ISBN   978-3-662-00226-1.
  13. Duke, BO (1968). "Reinfections with Onchocerca volvulus in cured patients exposed to continuing transmission". Bulletin of the World Health Organization. 39 (2): 307–9. PMC   2554563 . PMID   5303412.
  14. blaz (5 October 2009). "DETAILED THREAD ON CANKER TRICHOMONIASIS". pigeonbasics.com. copied from and citing Peters, Wim (1995). Fit to win : health, diagnosis and treatment in racing pigeons. Londin [sic]: Racing Pigeon. ISBN   978-0-85390-043-6.

Further reading